Industry fears that US FDA-CMS review could harm device innovation
This article was originally published in Clinica
Executive Summary
The US health department's proposal to establish a programme that would allow the FDA and the Centers for Medicare and Medicaid Services (CMS) to jointly review new medical devices under development is well-intended but may have negative consequences on innovation, says medtech industry association AdvaMed.